If you have not already registered for Full Text Access to The Journal, then visit our registration page.
Many supplements are available to the general public for a limited time on our SuppleNet page.


VOLUME 60   1999   SUPPLEMENT 1

Articles

3 Introduction. Pharmacoeconomics of Treatment-Resistant Schizophrenia. M. Annette Hanson, M.D., Symposium Chair
[PDF]

4 The Economic Impact of Schizophrenia. Dorothy P. Rice
[Abstract] [PDF]

7 Pharmacoeconomic Evaluation of Treatments for Refractory Schizophrenia: Clozapine-Related Studies. Dennis A. Revicki, Ph.D.
[Abstract] [PDF]

12 New Antipsychotic Agents: Emerging Clinical Profiles. Peter F. Buckley, M.D.
[Abstract] [PDF]

18 Clozapine for Refractory Schizophrenia: The Illinois Experience. Robert W. Buckman, Ph.D., and Randy D. Malan, R.Ph.
[Abstract] [PDF]

23 New vs. Old Antipsychotics: The Texas Experience. William H. Reid, M.D., M.P.H.
[Abstract] [PDF]

26 Pharmacoeconomics of Schizophrenia in the 21st Century. M. Annette Hanson, M.D.
[Abstract] [PDF]

28 Consensus Discussion.
[PDF]